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Introduction. Management of phenylketonuria (PKU) is achieved through low-phenylalanine (Phe) diet, supplemented with low-
protein food andmixture of free-synthetic (FS) amino acid (AA). Casein glycomacropeptide (CGMP) is a natural peptide released
in whey during cheese-making and does not contain Phe. Lacprodan® CGMP-20 used in this study contained a small amount
of Phe due to minor presence of other proteins/peptides. Objective. (e purpose of this study was to compare absorption of
CGMP-20 to FSAA with the aim of evaluating short-term eﬀects on plasma AAs as well as biomarkers related to food intake.
Methods. (is study included 8 patients, who had four visits and tested four drink mixtures (DM1–4), consisting of CGMP, FSAA,
or a combination. Plasma blood samples were collected at baseline, 15, 30, 60, 120, and 240 minutes (min) after the meal. AA
proﬁles and ghrelin were determined 6 times, while surrogate biomarkers were determined at baseline and 240min. A visual
analogue scale (VAS) was used for evaluation of taste and satiety. Results. (e surrogate biomarker concentrations and VAS
scores for satiety and taste were nonsigniﬁcant between the four DMs, and there were only few signiﬁcant results for AA proﬁles
(not Phe). Conclusion. CGMP and FSAA had the overall same nonsigniﬁcant short-term eﬀect on biomarkers, including Phe.
(is combination of FSAA and CGMP is a suitable supplement for PKU patients.
1. Introduction
Phenylketonuria (PKU) is an inborn error of metabolism. If
left untreated, severe brain damage will occur [1–3]. (e
primary aim of treatment of those suﬀering from PKU is to
control the blood phenylalanine (Phe) concentration in
order to prevent neurological damage [2]. PKU treatment is
based on a low-protein (LP) diet in combination with free-
synthetic (FS) amino acid (AA) supplements without Phe
and enriched with vitamins, minerals, trace elements, and in
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some products also fat and carbohydrates [1, 4, 5]. Dietary
AA supplements are administered to obtain optimal met-
abolic control by ensuring adequate levels of essential
AAs. Diet for life is recommended [6]. Compliance becomes
a challenge over time, especially in adolescence, and they
are often related to disagreeable taste and the current lim-
itations in available dietary products [7, 8]. In order to
achieve better compliance, the formulation of the AA sup-
plement should satisfy the need for better taste and easier
management [9]. (erefore, alternatives to conventional
treatment are investigated.
Casein glycomacropeptide (CGMP) is a 64-amino acid
peptide from cheese whey, which is rich in speciﬁc essential
AAs and is the only known natural protein free from Phe
[10–14]. Hence, CGMP is an alternative source of protein
for PKU patients. In this study, we tested the product Lac-
prodan CGMP-20, a highly puriﬁed CGMP product with
minimum 95% CGMP and a low level of Phe (0.16 g/100 g
AA) and above 78% protein. (e residual amount of Phe is
due to the presence of minor amounts of other proteins/
peptides. However, to ensure the supplement is nutritionally
adequate, it requires supplementation of the following AAs
to meet the standards of similar PKU supplements: tyrosine
(Tyr), tryptophan (Trp), arginine (Arg), histidine (His), leucine
(Leu), lysine (Lys), and methionine (Met) [15–17]. Lacprodan
CGMP-20 will be referred to as CGMP in this paper.
In this single-blinded, prospective, crossover interven-
tion study, we investigated the utilization and metabolic
short-term eﬀect on absorption of pure CGMP-20, FSAA,
and a combination of both, all consumed with a standardized
meal, by comparing selected relevant surrogate biomarkers.
We also evaluated taste and satiety. A second aim was to
investigate whether the small amount of Phe in CGMP-20
aﬀected the plasma Phe concentration signiﬁcantly.
2. Materials and Methods
2.1. Protocol. (e study was approved by the National
Committee on Health Research Ethics prior to the study (ID
H-3-2014-115), and all participants gave written consent
prior to start of the study.
2.2. Patient Recruitment. Patients were contacted by mail
and invited to participate. (ey were recruited from the
clinical PKU database, including all PKU patients diagnosed
and living in Denmark. Patients received compensation for
lost wages and travel expenses. Participants in the project
were invited to participate if theymet the following inclusion
criteria: diagnosis of classical PKU conﬁrmed by mutation
analysis and a known phe tolerance (12–20mg/kg) [18–20],
age≥ 15 years at inclusion, had received treatment with
a protein-restricted diet since the neonatal period, and were
willing and able to visit the PKU clinic four times.(e period
between visits varied from 24 hours to 1 month, since we
estimated this to be suﬃcient time for a wash-out period [21,
22]. Exclusion criteria were (1) <15 years at inclusion, (2) had
not followed the dietary treatment continuously, (3) had
a second chronic disease or condition, which potentially
could inﬂuence the PKU treatment and outcome, (4) treated
with BH4, or (5) pregnant, nursing, or planning to become
pregnant. Eight patients accepted to participate.
2.3. Study Design. (e primary purpose of this study was to
compare the absorption rate and absorbed amount of
peptide-bound AAs (CGMP-20∗) (both in its pure form or
supplemented with selected FSAAs) with an almost identical
mixture of FSAAs with the aim of evaluating the short-term
eﬀect on Phe and other AAs as well as biomarkers related
to food intake. All patients had four visits in the PKU
clinic. (e patients consumed a diﬀerent drink mixture
(DM1, DM2, DM3, and DM4) in random order at each visit
(blinded to the participants). (e order of the DM was
randomized by a doctor at the PKU clinic, who was not
otherwise involved in the study. CGMP/AA supplements:
four diﬀerent AA sources were tested. DM1: Lacprodan
CGMP-20. DM2: FSAA (equivalent AA proﬁle as DM1).
DM3: Lacprodan CGMP-20 and synthetic AA. DM4: FSAA
(equivalent AA proﬁle as DM3 but without Phe). DM2 had
the same AA proﬁle as DM1 consisting of pure CGMP in
order to evaluate this; DM3 consisted of CGMP supple-
mented with FSAA to make it nutritionally adequate and
suitable for patients with PKU and had a similar AA proﬁle
as DM4 (though this was without the 0.16 g Phe/100 g AA
present in CGMP). (e crossover study design made it
possible to evaluate the eﬀect of the Phe content in GMP.
Patients arrived fasting to the clinic in the morning and then
subjected to the ﬁrst venous blood samples (4ml) at time 0.
Subsequently, blood samples were drawn at 15, 30, 60, 120,
and 240 minutes (min) after ﬁnishing the meal. Taste was
evaluated right after consumption. At the end of the visit, all
participants were asked to evaluate satiety.
(e test meals consisted of a few selected food items
(homemade LP bread, butter, and jam) with individually
calculated amounts of fat and carbohydrates and only
a minimal content of protein and Phe from LP bread. (e
test meal was consumed in combination with DM, and
the individual intake was designed to cover 25% of the
daily requirement. In eachmeal, the total content of protein
was equivalent to 25% of 1 g per kg body weight per day
(1 g/kg/d). (e composition of the meal was calculated
after the Nordic Nutrition Recommendations (NNA) and
met the criteria for sex, age, and weight: 10–15% from
protein, 30–35% from fat, and 50–60% from carbohydrate.
After completing the trial, all participants would continue
their usual diet and AA supplements. An example of a meal
is shown in Table 1, and the content of DM1–4 is given in
Table 2.
2.4. Blood Samples. All participants had the following blood
samples drawn at start (time 0) before consuming the
meal/DM and at the end of the study (240min): glucose,
insulin, glucagon-like peptide-1(GLP-1), blood urea nitro-
gen (BUN), peptide tyrosine-tyrosine (PYY), cholecystoki-
nin (CCK), ghrelin, and AA proﬁles. Furthermore, ghrelin
and AA proﬁles were (besides at time 0) also measured at
15, 30, 60, 120, and 240min.
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2.4.1. BUN, Glucose, Insulin, Ghrelin, GLP-1, PYY, and
CCK. 2–4ml of blood was collected for each biomarker and
handled immediately according to protocols [23–28], placed
on ice, spinned at 2500 g for 10min at 4°C, and transferred
to speciﬁc glasses for further analyses. EDTA glasses for
(1) GLP-1 were added 200µl DPP-IV inhibitor and for
(2) ghrelin were added 100µl Pefabloc by using a 0.5ml syringe
(e samples for the total plasma AA proﬁle were frozen at−80°C and sent on dry ice for quantitative analysis of AA using
the stable-isotope dilution technique and HPLC-MS/MS [29].
2.5. Visual Analogue Scale (VAS). (is scale (http://www.
vastranslator.com) was presented to patients as a horizontal
line, ranking from “very hungry” (“0”) to “very satisﬁed”
(“100”) and from “bad taste” (“0”) to “good taste” (“100”) as
an application (APP) on iPad. (e patients were asked to
evaluate the taste of the DM shortly after intake and after
240min to determine the level of satiety.
2.6. Body Mass Index (BMI) and Fat Percentage. (ese were
measured at visit 1 with a body fat monitor (BF306, Omron
Healthcare, USA).
2.7. Diet Registration. (e patients had ﬁlled out a dietary
record covering the 24 hours before each visit. (ey were
instructed to eat similar food items every time to ensure that
the Phe level would be within the same range the day after.
(e registrations were calculated with Dankost (http://
dankost.dk/english).
2.8. Statistical Methods. All calculations were performed
using the software SPSS 22 or Microsoft Excel 2010 for
windows. Paired and unpaired t-tests and one- and two-way
ANOVA performed at a signiﬁcance level of α 0.05 were
used. (e statistical signiﬁcance level was at p< 0.05.
3. Results
3.1. Clinical Protocol. Eight patients (seven females, one
male), age 15–48 years (mean 33.25± SD 11.21), weight
47–85 kg (mean 72.8 + SD 15.9), and height 162–179 cm
(mean 170.1 + SD 5.4) were included in the study. Data for
each patient are presented in Table 3. Six out of eight (75%)
patients completed the study. Patient ID#4 had diﬃculties
eating the meal within 15min at visit one, which subsequently
delayed blood sampling up to 10min for each blood sample.
Patient ID#4 completed day 1 and day 2 as planned, but on
the third day, blood sampling was impossible, and for that
reason, visit 4 was cancelled and the patient excluded. Patient
ID#5 completed visit 1 and visit 2 but was unable to complete
day 3 and day 4 due to health problems.
3.2. Diet Registration. (e 24-hour diet record conﬁrmed
similar intake for each patient prior to the four test days.
3.3. Test Meals and DM. Intake of protein from DM sup-
plement was 25% of the daily recommendation of 1 g
protein/kg/day (mean volume 151.8 g (range 97.9–195.8)),
and the test meal provided fat and carbohydrates (Table 4).
All patients complied with the intake.
3.4. AA Proﬁles. AA proﬁles were compared in subgroups
(DM1 versusDM2 andDM3 versusDM4), since the respective
groups were identical concerning the AA composition. Sta-
tistical results were calculated between these subgroups.
(e area under the curve (AUC) (adjusted for baseline)
for total AA demonstrated insigniﬁcant diﬀerences between
DM1 and DM2 (p  0.852) as well as between DM3 and
DM4 (p  0.06).
We did ﬁnd signiﬁcant diﬀerences for the following
individual AA for AUC: DM1 and DM2: Lys (p  0.0287),
Asn (p  0.0210), and Asp (p  0.0047) and DM3 and
DM4: citrulline (p  0.0162). Results for all the AUC for
each AA are presented in Table 5. (e highest value for the
AUC for the individual AAwas Ala, Val, Ile, and Asp (DM1),
Pro (DM2), and Leu (DM3).
3.5. Plasma Concentrations of AA. (e peak plasma con-
centrations for AAs (given as mean values in percentage of
the premeal level) were as follows: DM1: the peak serum
concentrations were reached after 30min for 19 of 21(90%)
AAs. Glu reached a peak after 15min; Tyr only decreased
compared to baseline. DM2: four AAs peaked after 30min,
while 15 (71%) AAs peaked after 15 min. Citrulline
peaked after 60 min; Tyr decreased compared to time 0.
DM3: majority of the AAs peaked after 30 min (67%)
except for Asp, Met, and Gln, where the peaks were
reached after 15 min. Phe, Glu, citrulline, and Gly all
decreased compared to baseline. DM4: ﬁfteen AAs (71%)
peaked after 15 min, only ﬁve after 30 min, while cit-
rulline peaked after 60 min. All results are displayed in
Table 6.
Since most of the AAs peaked after either 15 or 30min,
comparison of the concentrations for each DM after 15min
versus 30min was performed to test for signiﬁcant dif-
ferences between these time points. (e following AAs
showed signiﬁcant changes between time 15 and time 30:
DM1: Ala (0.0474), Pro (0.0174), Val (0.0299), and Ile
(0.0294), DM2: Leu (0.0295), and DM4: Asp (0.0423). (ere
were no signiﬁcant changes for any AA in DM3. More
details are provided in Supplemental Table A.
(e paired t-test was used for comparison of the con-
centrations found in DM1 and DM2 and in DM3 and DM4,
respectively, at each time point, to test for signiﬁcant dif-
ferences between the four DMs. We found no signiﬁcant
diﬀerences at time 0. Plasma concentrations (µmol/l) after
Table 1: Example of a test breakfast meal including DM (calculated
individually for each participant).
DM (CGMP-20, AA, or CGMP+AA)
2 slices (80 g) of LP bread
Butter (20 g)
Jam (20 g)
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Table 3: Patient data, all with classic PKU: age, mutations, height, weight, BMI, and usual AA supplement.
Patient ID# Age Mutation 1 Mutation 2 Phenotype Height (cm) Weight (kg) BMI Usual AA product
1 48 c.1315+1G>A1 c.1315+1G>A1 Classic PKU 169 85 30 PreKUnil tablets
2 27 c.1315+1G>A1 c.1222C>T2 Classic PKU 174 62 20 XPhe energy
3 18 c.842C>T3 c.1315+1G>A1 Classic PKU 171 75 26 Avonil powder
4 16 c.1222C>T2 c.1315+1G>A1 Classic PKU 171 47 16 Avonil tablets
5 38 c.1315+1G>A1 c.1222C>T2 Classic PKU 179 79 25 PreKUnil tablets
6 46 c.814G>T4 c.1222C>T2 Classic PKU 173 94 31 PreKUnil tablets
7 34 c.473G>A5 c.1315+1G>A1 Classic PKU 162 53 20 PreKUnil tablets
8 39 c.1222C>T2 c.1222C>T2 Classic PKU 162 87.5 33 Avonil tablets
1(IVS12+1G>A); 2p.R408W; 3p.E280K; 4p.G272X; 5p.R158Q.
Table 2: Content of pure CGMP (g AA/100 g p) and DM1–4 (pr. 1000 g mixture) (CGMP and free-synthetic AA). DM1: 100% CGMP:
158.46 g the content of each AA displayed below. DM2: 100% FSAA (the total amount of AA is shown below). DM3: 119.04 g from CGMP
(+AA the additional amount of AA from FSAA). DM4: 100% FSAA.
CGMP-20 AA DM1: LacprodanCGMP-20: 158.46 g∗ DM2:FSAA DM3: LacprodanCGMP-20: 119.04 g∗ +FSAA DM4:FSAA
g AA/100 g protein Total amount of AA (g)
6.4 Ala 8.57 8.40 6.44 6.31
0.3 Arg 0.44 0.43 4.85∗ 4.85
9.2 Asp 12.08 11.83 9.07 8.89
0.08 Cys 0.15 0.15 0.11 0.11
21.1 Glu 26.53 25.99 19.93 19.52
1.2 Gly 1.53 1.50 1.15 1.13
0.2 His 0.16 0.16 3.0∗ 3.04
11.5 Ile 14.50 14.21 10.89 10.67
2.5 Leu 3.12 3.06 12.11∗ 12.06
6.4 Lys 8.46 8.29 7.37∗ 7.24
2 Met 2.92 2.85 3.62∗ 3.57
0.2 Phe 0.20 0.20 0.15 0
12.6 Pro 16.45 16.11 12.36 12.10
8.5 Ser 10.46 10.25 7.86 7.70
18.1 (r 23.62 23.14 17.74 17.38
0.04 Trp 0.00 — 2.44∗ 2.44
0.06 Tyr 0.05 0.05 10.81∗ 10.81
9.5 Val 11.76 11.52 8.83 8.65
— Citric acid powder — — 14.40 1.40
— Citric acid solution (50% w/w in water) 11.20 — — —
— Tropical twist ﬂavour (IFF SC401962) 1.75 1.75 1.75 1.80
— Sucrose 73.00 73.00 80.00 80.00
— Water 755.59 787.12 751.95 780.17
109.88 Total 1000.00 1000.00 1000.00 1000.00
— DM 1 2 3 4
81 Protein equivalent (g/100 g) 12.00 12.00 12.00 12.00
— Carbohydrate (g/100 g) 7.46 7.30 8.12 8.00
— Fat (g/100 g) 0.03 0 0.02 0
— Energy (kcal/100 g) 78 77 81 80∗Part of the AA content comes from CGMP and part comes from additional FSAA: Arg: 0.33 (CGMP) + 4.52 (AA) 4.85, His 0.12 (CGMP) + 2.92 (AA)
3.04, Leu: 2.35 (CGMP) + 9.76 (AA) 12.11, Lys: 6.36 (CGMP) + 1.01 (AA) 7.37, Met: 2.19 (CGMP) + 1.43 (AA) 3.62, Trp: 0.00 (CGMP) + 2.44 (AA) 2.44,
Tyr: 0.04 (CGMP) + 10.77 (AA) 10.81.
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intake of the DM and test meal for all AAs presented as %.
Comparison between DM1+2 and DM3+4 gave the fol-
lowing results: time 15: DM1+2: Tyr: 0.0228, Asp: 0.0136, and
citrulline: 0.0378; DM3+4: Pro: 0.0455, Val: 0.0204, and(r:
0.0239; time 30: DM1+2: Leu: 0.0178, Ile: 0.0021, Asn: 0.0038,
and Asp: 0.0362; DM3+4: Ser: 0.0031, Pro: 0.0486, (r:
0.0027, His: 0.0108, Tyr: 0.0412, and citrulline: 0.0409; time
60: DM1+2: Asp: 0.0060 and citrulline: 0.0100; DM3+4:
Pro: 0.0003, Val: 0.0088, (r: 0.0270, and Asp: 0.0155; time
120: DM3+4: citrulline:0.0364; and time 240: DM1+2: Asp:
0.0288. (ere were no signiﬁcant diﬀerences at time 0.
Compared to baseline values, ghrelin values demon-
strated a signiﬁcant decrease at 30, 60, and 120min for DM1,
at 30min for DM2, at 60 and 120min for DM3, and at 30, 60,
and 120min for DM4, respectively. Final levels decreased 7%
for DM1, increased 10% for DM2 and 5% for DM3, and
remained unchanged in DM4, all compared to baseline.
Table 7 displays results (% compared to baseline) and the
Table 4: Intake of DM (water +CGMP mixture powder total volume) and standard meal in grams (g) and energy (kilojoule (kJ) and
energy % (E %)).
Patient ID 1 2 3 4 5 6 7 8 Mean SD
Powder (g) 41 30 36 21 38 45 27 44 35 8
Water (g) 136 99 120 77 126 151 83 139 116 25
LP bread (g) 70 90 170 100 82 70 96 80 95 30
Butter (g) 23 23 35 26 21 21 23 19 24 5
Marmalade (g) 40 40 40 42 40 40 40 40 40 1
Energy (kJ) 2324 2330 3445 2405 2324 2327 2316 2322 2474 368
Protein (g) 22 16 20 13 20 24 14 23 19 4
Protein E (%) 16 12 10 9 15 18 10 17 13 3
Fat (g) 20 20 32 23 19 18 21 18 21 4
Fat E (%) 32 33 34 35 30 29 33 28 32 2
Carbohydrate (g) 70 75 111 78 74 71 76 74 79 12
Carbohydrate E (%) 52 56 56 57 55 53 57 56 55 2
Table 5: Results for the AUC (µmol/l over time) for all AAs (adjusted for baseline (time 0)). Signiﬁcant diﬀerences for the following AAs for
the area under the curve (AUC) minus baseline: DM1 and 2: Lys (p  0.0287), Asn (p  0.0201), and Asp (p  0.0046) and DM3 and 4:
citrulline (p  0.0162).
DM
1 2 3 4
Mean SD Mean SD Mean SD Mean SD
Gly −1145 12734 11361 20714 −16590 15386 11709 9483
Ala 38797 10277 29471 5292 8397 3693 20653 5239
Ser 8021 2312 6262 680 −1264 2222 2180 1230
Pro 28232 3802 33492 7623 9353 2444 15950 2204
Val 46664 5818 33878 7511 14370 5722 24624 7244
(r 38627 7843 35865 3144 13558 1338 20698 2662
Leu −3102 499 −2979 786 6899 1798 5206 1564
Ile 26638 2253 21551 1691 9666 1474 8429 1146
Lys 16623 3356 5005 3255 3932 2076 7342 2542
Asn 3036 688 910 409 1838 978 1129 652
Met 1976 580 1848 230 842 429 3026 1961
His −419 768 −1133 677 −1036 1151 1003 697
Phe −6717 11135 −2778 6468 −24356 10869 −8944 9170
Tyr −3376 592 −4000 649 6672 1012 6019 1622
Glu 123 399 −305 541 −2302 1004 −988 782
Gln 34247 7716 39614 10878 −4902 4414 9870 7528
Asp 1399 413 −254 239 −682 490 −469 217
Trp −1364 403 −1078 412 804 849 994 484
Orn 1167 818 733 621 799 724 1288 304
Arg −505 1292 −100 1136 −1121 1310 1047 941
Cit −1115 634 790 647 −2193 549 305 652
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Table 6: Plasma concentrations (µmol/l) after intake of the DM and test meal for all AAs presented as % compared to time 0 (1).
Comparison between DM1+2 and DM3+4 gave the following results: time 15: DM1+2: Tyr: 0.0228, Asp: 0.0136, citrulline: 0.0378; DM3+4:
Pro: 0.0455, Val: 0.0204, (r: 0.0239; time 30: DM1+2: Leu: 0.0178, Ile: 0.0021, Asn: 0.0038, Asp: 0.0362; DM3+4: Ser: 0.0031, Pro: 0.0486,
(r: 0.0027, His: 0.0108, Tyr: 0.0412, citrulline: 0.0409; time 60: DM1+2: Asp: 0.0060, citrulline: 0.0100; DM3+4: Pro: 0.0003, Val: 0.0088,(r:
0.0270, Asp: 0.0155; time 120: DM3+4: citrulline: 0.0364; time 240: DM1+2: Asp: 0.0288. (ere were no signiﬁcant diﬀerences at time 0.
Time
15 30 60 120 240
Mean SD Mean SD Mean SD Mean SD Mean SD
DM1
Gly 0.961 0.339 1.062 0.616 0.944 0.500 1.011 0.355 0.963 0.717
Ala 1.656 0.435 2.340 0.653 1.940 0.462 1.510 0.419 1.233 0.328
Ser 1.669 0.434 2.189 0.615 1.535 0.434 1.024 0.172 1.194 0.440
Pro 2.904 0.886 3.886 1.117 2.819 1.256 1.782 0.303 1.523 0.374
Val 1.977 0.510 2.509 0.698 2.255 0.422 1.712 0.257 1.583 0.310
(r 2.594 0.544 3.885 0.867 2.855 0.813 2.013 0.229 1.832 0.829
Leu 1.365 0.152 1.425 0.155 0.995 0.094 0.582 0.162 0.828 0.143
Ile 5.815 1.849 7.033 1.190 5.198 0.841 3.426 0.464 2.603 0.517
Lys 2.195 0.794 2.258 0.500 1.828 0.690 1.468 0.653 1.263 0.734
Asn 1.666 0.251 2.003 0.399 1.412 0.313 1.012 0.091 1.218 0.414
Met 2.255 0.714 2.275 0.684 1.690 0.522 1.165 0.235 1.071 0.387
His 1.000 0.116 1.153 0.245 1.034 0.231 0.842 0.118 1.060 0.339
Phe 0.942 0.130 1.012 0.189 0.990 0.199 0.935 0.131 0.976 0.271
Tyr 0.816 0.143 0.863 0.245 0.765 0.170 0.599 0.134 0.647 0.136
Glu 1.302 0.307 1.243 0.149 1.061 0.180 0.915 0.127 0.961 0.173
Gln 1.278 0.204 1.309 0.296 1.291 0.277 1.245 0.208 1.242 0.402
Asp 1.783 0.495 2.225 0.760 1.592 0.327 1.076 0.245 1.104 0.316
Trp 0.980 0.105 1.116 0.188 0.906 0.155 0.725 0.145 0.808 0.256
Orn 1.288 0.340 1.520 0.501 1.287 0.366 0.989 0.175 1.006 0.325
Arg 1.041 0.135 1.220 0.272 1.024 0.198 0.876 0.193 0.963 0.242
Cit 0.889 0.251 1.075 0.316 0.809 0.228 0.744 0.244 0.939 0.467
DM2
Gly 1.238 0.926 1.197 0.745 1.081 0.938 1.227 0.796 0.979 0.654
Ala 1.603 0.354 1.664 0.483 1.620 0.447 1.312 0.335 1.163 0.379
Ser 1.653 0.297 1.697 0.546 1.457 0.204 1.102 0.213 1.083 0.169
Pro 3.177 0.867 3.052 1.017 2.846 1.185 2.291 1.110 1.617 0.435
Val 1.647 0.579 1.856 0.730 1.719 0.397 1.544 0.560 1.420 0.497
(r 2.555 0.512 3.182 0.977 2.808 0.691 2.254 0.735 1.957 0.447
Leu 1.389 0.255 1.225 0.196 0.983 0.094 0.635 0.129 0.810 0.160
Ile 4.892 2.668 4.640 2.055 4.192 1.679 3.112 1.420 2.572 0.857
Lys 1.714 0.725 1.420 0.530 1.280 0.341 1.046 0.218 1.023 0.438
Asn 1.518 0.172 1.314 0.359 1.155 0.124 0.954 0.197 1.046 0.270
Met 1.992 0.542 1.830 0.641 1.570 0.328 1.220 0.173 1.085 0.184
His 1.114 0.208 1.045 0.308 0.993 0.175 0.823 0.178 0.944 0.171
Phe 1.055 0.227 0.952 0.195 0.956 0.109 0.964 0.159 1.036 0.130
Tyr 0.951 0.231 0.812 0.187 0.692 0.132 0.586 0.145 0.606 0.125
Glu 1.130 0.182 1.087 0.177 1.016 0.165 0.897 0.222 0.964 0.202
Gln 1.537 0.427 1.508 0.350 1.478 0.531 1.199 0.393 1.271 0.390
Asp 1.200 0.426 1.132 0.266 0.880 0.155 0.814 0.230 1.005 0.190
Trp 1.075 0.304 0.996 0.361 0.871 0.263 0.768 0.171 0.884 0.171
Orn 1.227 0.290 1.081 0.287 1.067 0.211 1.084 0.302 1.079 0.275
Arg 1.207 0.286 1.111 0.395 1.084 0.215 0.927 0.215 0.931 0.258
Cit 1.118 0.525 1.136 0.404 1.211 0.349 1.121 0.359 1.030 0.359
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t-test for all levels and values (mean and SD) in Supple-
mental Table B.
None of the biomarkers GLP-1, PYY, BUN, CCK, in-
sulin, and glucose showed signiﬁcant changes from baseline
(premeal) to the end of the study period (240min after meal
and DM). Results for biomarkers are presented in Figure 1
(% compared to baseline) and values (mean +/− SD) in
Supplemental Table C.
Table 6: Continued.
Time
15 30 60 120 240
Mean SD Mean SD Mean SD Mean SD Mean SD
DM3
Gly 0.809 0.355 0.913 0.337 0.822 0.621 0.772 0.318 0.804 0.679
Ala 1.206 0.304 1.435 0.302 1.171 0.192 1.085 0.277 0.987 0.141
Ser 1.210 0.211 1.248 0.262 0.941 0.194 0.862 0.292 0.900 0.200
Pro 1.777 0.313 1.838 0.349 1.471 0.234 1.278 0.415 1.126 0.242
Val 1.459 0.274 1.715 0.330 1.228 0.117 1.314 0.572 1.078 0.143
(r 1.625 0.368 1.851 0.471 1.635 0.217 1.438 0.463 1.325 0.293
Leu 2.282 0.435 2.328 0.442 1.658 0.366 1.091 0.617 0.887 0.141
Ile 3.524 1.089 3.675 0.890 2.498 0.721 1.736 1.234 1.380 0.386
Lys 1.632 0.560 1.662 0.712 1.389 0.599 0.943 0.117 0.874 0.189
Asn 1.630 0.329 1.534 0.429 1.353 0.335 1.034 0.430 0.980 0.202
Met 1.826 0.370 1.754 0.507 1.255 0.116 1.070 0.374 0.865 0.180
His 1.049 0.153 1.153 0.240 0.915 0.137 0.900 0.264 0.895 0.129
Phe 0.889 0.111 0.911 0.104 0.843 0.100 0.879 0.140 0.910 0.119
Tyr 1.645 0.244 1.985 0.713 1.723 0.437 1.667 0.295 1.305 0.248
Glu 0.950 0.144 0.951 0.152 0.801 0.189 0.756 0.221 0.774 0.111
Gln 1.170 0.104 1.061 0.223 1.036 0.120 0.911 0.148 0.920 0.093
Asp 0.953 0.291 1.111 0.138 0.998 0.158 0.755 0.221 0.724 0.170
Trp 1.244 0.272 1.455 0.302 1.165 0.382 1.071 0.444 0.950 0.383
Orn 1.259 0.247 1.374 0.230 1.147 0.222 1.064 0.335 0.977 0.195
Arg 1.216 0.226 1.236 0.331 0.982 0.138 0.869 0.213 0.835 0.163
Cit 0.815 0.158 0.802 0.173 0.649 0.163 0.642 0.141 0.842 0.211
DM4
Gly 1.179 0.781 1.304 0.630 0.920 0.445 1.230 0.433 1.183 0.690
Ala 1.546 0.395 1.552 0.278 1.463 0.406 1.304 0.157 1.003 0.378
Ser 1.521 0.336 1.419 0.228 1.196 0.382 0.978 0.120 0.961 0.347
Pro 2.499 1.154 2.357 0.774 2.003 0.704 1.509 0.287 1.135 0.429
Val 1.861 0.438 1.865 0.450 1.528 0.297 1.511 0.913 1.263 0.491
(r 2.067 1.025 2.389 0.795 2.069 0.687 1.654 0.224 1.380 0.525
Leu 2.237 0.667 1.981 0.433 1.579 0.482 0.995 0.277 0.829 0.279
Ile 3.681 1.813 3.072 1.203 2.667 1.251 1.481 0.582 1.132 0.457
Lys 1.671 0.782 1.385 0.292 1.429 0.704 1.184 0.389 1.179 0.589
Asn 1.588 0.591 1.502 0.439 1.291 0.342 1.008 0.191 0.851 0.231
Met 2.527 1.706 2.337 1.887 1.956 2.094 1.503 1.681 1.035 0.763
His 1.237 0.231 1.261 0.135 1.140 0.270 1.004 0.153 0.981 0.342
Phe 1.054 0.126 0.981 0.109 0.947 0.141 0.942 0.108 0.921 0.293
Tyr 1.548 0.594 1.524 0.559 1.606 0.723 1.667 0.568 1.347 0.525
Glu 1.123 0.205 1.013 0.191 0.950 0.221 0.823 0.168 0.893 0.407
Gln 1.236 0.246 1.150 0.160 1.120 0.211 1.107 0.196 0.911 0.319
Asp 1.121 0.261 0.964 0.149 0.854 0.234 0.819 0.177 0.860 0.343
Trp 1.505 0.436 1.403 0.272 1.252 0.345 1.031 0.147 1.010 0.355
Orn 1.470 0.405 1.376 0.200 1.337 0.302 1.105 0.153 0.992 0.314
Arg 1.477 0.315 1.344 0.238 1.138 0.218 0.967 0.116 0.940 0.314
Cit 1.132 0.285 1.105 0.216 1.201 0.603 0.989 0.231 0.971 0.413
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3.6. VAS Score. (e question “how satisﬁed are you?” ob-
tained the following nonsigniﬁcant results: DM1 (mean 36,
SD 18), DM2 (mean 41, SD 16), DM3 (mean 28, SD 27), and
DM4 (mean 35, SD 30). (e results for the other question
“how does the DM taste?” were as follows: DM1 (mean 46,
SD 31), DM2 (mean 44, SD 22), DM3 (mean 36, SD 28), and
DM4 (mean 26, SD 22). All comparisons (DM1 and DM2,
DM3 and DM4, but also DM3 compared to DM1 and DM2,
resp.) were statistically insigniﬁcant.
4. Discussion
(is study evaluated the metabolic short-term eﬀect of
CGMP compared to an almost identical combination
of FSAA by repeated measurements. One of the most
important ﬁndings was that the residual content of Phe
in DM3 did not aﬀect the plasma level signiﬁcantly
compared to DM4 at any time which support data from
Ney et al. [11].
Over the last 8 years, CGMP has been investigated
in mice studies and a few human studies to evaluate
safety, acceptability, and eﬃcacy of CGMP as a nutritional
supplement for treatment of PKU [11–13, 15, 30, 31]. (e
present study supports the conclusions of these studies.
(e slower absorption of most of the AA in DM1 and
DM3, which contained CGMP, compared to DM2 and DM4,
which contained only FSAA, could be explained by the fact
that CGMP delay the absorption in the gut. (e fact that Tyr
increased in DM3 and DM4, but only decreased without peak
in DM1 and DM2, is assumed to be caused by the low content
in DM1 and DM2. Tyr and Trp both peaked at 30min for
DM3 compared to 15min for DM4, suggesting that the
content of Tyr and Trp in the CGMP mixtures were me-
tabolized less rapidly than the FSAA. (e Phe/Tyr ratio de-
creased over time with 30% in both DM3 and DM4, while it
increased (caused by the low-Tyr concentration in DM1 and
DM2) with 50% for DM1 and 70% for DM2. (e Phe/Tyr
ratio is an important measure because a high ratio can have
a long-term negative eﬀect on executive functions [32].
(e AUC for “total AA” was not associated with ab-
sorption rate. We also calculated the AUC for each AA and
compared with peak values to determine complete ab-
sorption and absorption rate, and we did ﬁnd signiﬁcant
diﬀerences for Lys, Asn, and Asp for DM1 and DM2 and for
citrulline for DM3 and DM4. None of the LNAA (extra-
added in DM3 and matched in DM4) was signiﬁcantly
diﬀerent.
Ala, Pro, Val, and Ile demonstrated a signiﬁcant increase
from 15 to 30min for DM1, while only Leu in DM2 and Asp
in DM4 decreased signiﬁcantly, which indicate a better
absorption of pure CGMP. (e fact that none of the AA in
DM3 changed signiﬁcantly could be the inﬂuence of the
extra-added AA (LNAA and Lys). In contrast, we did see
signiﬁcant diﬀerences between several AAs by comparison
between DM1 and DM2 and between DM3 and DM4 at each
time point. Especially His, Tyr, and Trp are noteworthy for
DM3 and DM4, since they are FSAAs added to the pure
CGMP. Also, (r, Ile, and Val are of certain interest, since
the natural content of these three AAs in CGMP is high [33].
(e high content of these AAs and addition of extra-LNAA
to the CGMP oﬀer an additional positive eﬀect, since LNAA
competes for transport across the blood-brain barrier (BBB)
via the L-type amino acid transporter (LAT1) [34, 35]. High
Phe in plasma diminishes uptake of Tyr and Trp into the
brain, and this results in reduced formation of neuro-
transmitters [36]. (is imbalance is possibly the major cause
of disturbed brain development in PKU patients [37]. Each
Table 7: Ghrelin levels over time, presented as % relative to start value (time 0) + SD and p value.
DM1 DM2 DM3 DM4
Time Relative(%)
SD
(%) p value
Relative
(%)
SD
(%) p value
Relative
(%)
SD
(%) p value
Relative
(%)
SD
(%) p value
0 100 — — 100 — — 100 — — 100 — —
15 95 12 0.266 88 11 0.056 90 13 0.171 75 22 0.050
30 82 5 0.006∗ 83 15 0.035∗ 78 19 0.055 80 10 0.015∗
60 81 13 0.030∗ 84 16 0.068 80 12 0.013∗ 75 11 0.006∗
120 81 10 0.020∗ 84 15 0.088 75 14 0.011∗ 74 13 0.010∗
240 93 18 0.454 110 20 0.180 105 25 0.473 100 34 0.986∗Signiﬁcant.
0%
50%
100%
150%
200%
250%
GLP-1
(pmol/L)
PYY 3-36
(pg/ml)
Urea
(mmol/L)
CCK
(pmol/L)
Insulin
(pmol/L)
Glucose
(mmol/L)
Drink 1
Drink 2
Drink 3
Drink 4
Figure 1: Results (mean +/− SD) for the following biomarkers:
glucose, insulin, GLP-1, PYY, BUN, and CCK. None of them
demonstrated signiﬁcant changes from baseline (premeal) to the
end of the study period (240min after meal and DM).
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LNAA has individual aﬃnity relation to LAT1 [38]. Several
studies have shown the positive blocking eﬀect of LNAA
which reduces Phe entering the brain [39–41]. Matalon
et al. [17] demonstrated a decrease in Phe in the blood up to
50% using LNAA tablets and emphasized that LNAA in
a speciﬁc mixture inhibits Phe uptake already in the gut
[16, 42]. Administrations of Val, Ile, and Leu have proved
to reduce Phe concentrations in the cerebrospinal ﬂuid of
humans [43].
All biomarkers remained unchanged by comparing
time 0 and 240min, and there were no signiﬁcant changes
in plasma Phe despite the residual amount of Phe in CGMP
in line with ﬁndings from Ney et al. [11, 13]. (is study
demonstrated that AA in CGMP is absorbed as eﬃcient as an
identical mixture of FSAA.
All the DMs demonstrated a decreasing eﬀect on ghrelin
after the meal. Ghrelin values showed signiﬁcant decreases
at 30, 60, and 120min for DM1, at 30min for DM2, at 60
and 120min for DM3, and at 30, 60, and 120min for DM4.
Low-ghrelin concentrations are associated with a feeling of
satiety [44, 45]. By only evaluating DM1 and DM2, it could
indicate that satiety is reached faster for CGMP. However,
VAS scores for satiety did not show any signiﬁcant diﬀerence
between DM1 and DM2, nor between DM3 and DM4.
BUN was nonsigniﬁcantly lower for DM1 and DM3
compared to DM2 and DM4, which potentially could sug-
gest a more eﬃcient utilization of GMP compared to AA, as
found by van Calcar et al. [13]. Similar ﬁndings have been
reported by Ney et al. [46]. However, our present short-term
study was not able to support these ﬁndings.
GLP-1 promotes insulin secretion and reduces appetite
and reached the highest (nonsigniﬁcant) level with DM3
after 240min (118%) which may indicate that satiety was
better obtained with DM3 compared with DM1, DM2, and
DM4. (is ﬁnding concurs with previous studies, showing
that GMP promotes satiety [14]. PYY also reduces appetite
and reached the highest value for DM3 (111%). CCK is
a peptide hormone in the gastrointestinal system responsible
for stimulating the digestion of fat and protein. (e wide
variation from a decrease of 18% in DM3 to an increase of
33% in DM4 was unexpected, since CCK is expected to rise
after a mixed meal [23].
A limitation of this study was the small number of
patients. However, it was important for the study design to
select as homogeneous a test population as possible (only
early-treated classical PKU conﬁrmed by mutation analysis),
resulting in exclusion of a number of patients.
(ree patients had a BMI over 30 and were deﬁned as
obese, one slightly obese, three had a normal BMI, and one
had a BMI below normal.(e patients were receiving dosage
after their actual weight, which means that the patients that
were categorized with normal BMI received less DM per kg
lean body mass.
Although this study demonstrated nonsigniﬁcant
changes for almost all biochemical markers, it is important
to notice that this study only replaced a single meal and
a long-term eﬀect could be diﬀerent. Based on the current
results, we consider CGMP to be a safe alternative to FSAA
but should be supplemented with additional FSAA to make
it nutritionally adequate and potential also with other nu-
trients as fat, carbohydrates, vitamins, and minerals to create
an easy-to-use supplement for patients with PKU. If CGMP
products substitute FSAA completely, it is necessary to
carefully monitor if the small content of Phe will have an
impact on the blood level in the long term. If Phe levels
increase, restrictions of the LP diet must be implemented to
balance and control the Phe intake and blood level. Further
studies are needed to evaluate the long-term impact and
eﬃcacy of CGMP in the management of PKU.
5. Conclusion
Dietary management of PKU should be lifelong, and good
compliance is crucial for a good outcome. CGMP did not
change any of the biomarkers signiﬁcantly compared to free-
synthetic AA when consumed with a test meal in PKU
patients.(e residual amount of Phe in CGMP did not aﬀect
the plasma Phe level signiﬁcantly. Based on these data, we
consider CGMP to be a suitable alternative as supplement
for PKU treatment. However, further research is needed to
determine the long-term eﬀects and safety of CGMP. (is
study demonstrates that CGMP has the same short-term
eﬀect as FSAA.
Abbreviations
CGMP: Casein glycomacropeptide, CGMP-20 (product
name Lacprodan CGMP-20)
PKU: Phenylketonuria
AA: Amino acid(s)
FSAA: Free-synthetic AA
BBB: Blood-brain barrier
BUN: Blood urea nitrogen
GLP-1: Glucagon-like peptide-1
CCK: Cholecystokinin
PYY: Peptide tyrosine-tyrosine
DM: Drink mix
Ala: Alanine
Arg: Arginine
Asn: Asparagine
Asp: Aspartate
Cys: Cysteine
Glu: Glutamine
Gly: Glycine
His: Histidine
Ile: Isoleucine
Leu: Leucine
Lys: Lysine
Met: Methionine
Phe: Phenylalanine
Pro: Proline
Ser: Serine
(r: (reonine
Trp: Tryptophan
Tyr: Tyrosine
Val: Valine
PAH: Phenylalanine hydroxylase
VAS: Visual analogue score
Journal of Nutrition and Metabolism 9
LP: Low protein
min: Minutes
SD: Standard deviation
kJ: Kilojoule.
Disclosure
Kirsten Kiær Ahring is an industrial PhD student sponsored
by AFI and (e Danish Agency for Science, Technology
and Innovation.
Conflicts of Interest
(e authors declare that they have no conﬂicts of interest.
Authors’ Contributions
All authors have made a substantial contribution to the
design and interpretation of data for the work, revised it
critically, and been presented for the ﬁnal version to be
published. Erik Jensen, Kirsten K. Ahring, and Lisbeth B.
Møller were involved in designing the study. Kirsten K.
Ahring was involved in collecting all the data and writing the
main manuscript.
Acknowledgments
(e authors would like to thank Arla Foods Ingredients and
(e Danish Agency for Science, Technology and Innovation
for funding, the PKU patients for participating in the study,
nurse Signe Larsen (PKU clinic, Kennedy Centre) for per-
forming the blood sampling, and lab technicians Søren
Andresen and Marianne Falck (University of Copenhagen)
for performing the blood analyses and assisting in handling
of blood samples.
Supplementary Materials
Table A. Results for all AA at time 0, 15, 30, 60, 120, and 240
(Mean and SD). Table B. Ghrelin results for time 0, 15, 30, 60,
120, and 240 (Mean and SD). Table C. Results for glucose,
insulin, GLP-1, PYY, BUN, and CCK (Mean ± SD). None of
them demonstrated signiﬁcant changes from baseline (pre-
meal) to end of study period (240min after meal and DM).
(Supplementary Materials)
References
[1] J. J. Mitchell, Y. J. Trakadis, and C. R. Scriver, “Phenylalanine
hydroxylase deﬁciency,” Genetics in Medicine, vol. 13, no. 8,
pp. 697–707, 2011.
[2] N. Blau, “Genetics of phenylketonuria: then and now,”
Human Mutation, vol. 37, no. 6, pp. 508–515, 2016.
[3] M. Giovannini, E. Verduci, E. Salvatici, S. Paci, and E. Riva,
“Phenylketonuria: nutritional advances and challenges,”
Nutrition and Metabolism, vol. 9, no. 1, p. 7, 2012.
[4] H. L. Levy, “Nutritional therapy for selected inborn errors
of metabolism,” Journal of the American College of Nutrition,
vol. 8, no. 1, pp. 54S–60S, 1989.
[5] A. MacDonald, J. C. Rocha, M. van Rijn, and F. Feillet,
“Nutrition in phenylketonuria,” Molecular Genetics and
Metabolism, vol. 104, pp. S10–S18, 2011.
[6] R. A. Williams, C. D. S. Mamotte, and J. R. Burnett, “Phe-
nylketonuria: an inborn error of phenylalanine metabolism,”
Clinical Biochemist Reviews, vol. 29, no. 1, pp. 31–41, 2008.
[7] A. MacDonald, H. Gokmen-Ozel, M. van Rijn, and
P. Burgard, “(e reality of dietary compliance in the man-
agement of phenylketonuria,” Journal of Inherited Metabolic
Disease, vol. 33, no. 6, pp. 665–670, 2010.
[8] A. Aguiar, K. Ahring, M. F. Almeida et al., “Practices in
prescribing protein substitutes for PKU in Europe: no uni-
formity of approach,” Molecular Genetics and Metabolism,
vol. 115, no. 1, pp. 17–22, 2015.
[9] F. J. van Spronsen and P. Burgard, “(e truth of treating
patients with phenylketonuria after childhood: the need for
a new guideline,” Journal of Inherited Metabolic Disease,
vol. 31, no. 6, pp. 673–679, 2008.
[10] B. Chabance, P. Marteau, J. C. Rambaud et al., “Casein peptide
release and passage to the blood in humans during digestion
of milk or yogurt,” Biochimie, vol. 80, no. 2, pp. 155–165, 1998.
[11] D. M. Ney, S. T. Gleason, S. C. van Calcar et al., “Nutritional
management of PKU with glycomacropeptide from cheese
whey,” Journal of Inherited Metabolic Disease, vol. 32, no. 1,
pp. 32–39, 2009.
[12] P. Solverson, S. G. Murali, A. S. Brinkman et al., “Glyco-
macropeptide, a low-phenylalanine protein isolated from
cheese whey, supports growth and attenuates metabolic stress
in the murine model of phenylketonuria,” American Journal
of Physiology: Endocrinology and Metabolism, vol. 302, no. 7,
pp. E885–E895, 2012.
[13] S. C. van Calcar, E. L.MacLeod, S. T. Gleason et al., “Improved
nutritional management of phenylketonuria by using a diet
containing glycomacropeptide compared with amino acids,”
American Journal of Clinical Nutrition, vol. 89, no. 4,
pp. 1068–1077, 2009.
[14] S. C. van Calcar and D. M. Ney, “Food products made with
glycomacropeptide, a low-phenylalanine whey protein,
provide a new alternative to amino acid-based medical foods
for nutrition management of phenylketonuria,” Journal of the
Academy of Nutrition and Dietetics, vol. 112, no. 8, pp. 1201–
1210, 2012.
[15] C. E. Laclair, D. M. Ney, E. L. MacLeod, and M. R. Etzel,
“Puriﬁcation and use of glycomacropeptide for nutritional
management of phenylketonuria,” Journal of Food Science,
vol. 74, no. 4, pp. E199–E206, 2009.
[16] R. Matalon, K. Michals-Matalon, G. Bhatia et al., “Double
blind placebo control trial of large neutral amino acids in
treatment of PKU: eﬀect on blood phenylalanine,” Journal
of Inherited Metabolic Disease, vol. 30, no. 2, pp. 153–158,
2007.
[17] R. Matalon, K. Michals-Matalon, G. Bhatia et al., “Large
neutral amino acids in the treatment of phenylketonuria
(PKU),” Journal of Inherited Metabolic Disease, vol. 29, no. 6,
pp. 732–738, 2006.
[18] P. Guldberg and F. Guttler, “Mutations in the phenylalanine
hydroxylase gene: methods for their characterization,” Acta
Paediatrica, vol. 83, no. 407, pp. 49–56, 1994.
[19] F. Gu¨ttler and H. Lou, “Phenylketonuria and hyper-
phenylalaninemia,” in Inborn Metabolic Diseases: Diagnosis
and Treatment, J. Fernandes, J.-M. Saudubray, and K. Tada,
Eds., pp. 161–174, Springer, Berlin, Heidelberg, Germany, 1990.
[20] F. Guttler, “Hyperphenylalaninemia: diagnosis and classiﬁ-
cation of the various types of phenylalanine hydroxylase
10 Journal of Nutrition and Metabolism
deﬁciency in childhood,” Acta paediatrica Scandinavica.
Supplement, vol. 280, pp. 1–80, 1980.
[21] G. N. (ompson and D. Halliday, “Signiﬁcant phenylalanine
hydroxylation in vivo in patients with classical phenylke-
tonuria,” Journal of Clinical Investigation, vol. 86, no. 1,
pp. 317–322, 1990.
[22] G. N. (ompson, P. J. Pacy, R. W. Watts, and D. Halliday,
“Protein metabolism in phenylketonuria and Lesch–Nyhan
syndrome,” Pediatric Research, vol. 28, no. 3, pp. 240–246,
1990.
[23] J. F. Rehfeld, “Accurate measurement of cholecystokinin in
plasma,” Clinical Chemistry, vol. 44, no. 5, pp. 991–1001, 1998.
[24] ABX H., Diagnostic test for glucose, 2008.
[25] Diagnostic Test for Blood Urea Nitrogen (BUN), 2014, http://
www.horiba.com.
[26] M. A. Nauck, N. Kleine, C. Ørskov, J. J. Holst, B. Willms, and
W. Creutzfeldt, “Normalization of fasting hyperglycaemia by
exogenous glucagon-like peptide 1 (7-36 amide) in type 2
(non-insulin-dependent) diabetic patients,” Diabetologia,
vol. 36, no. 8, pp. 741–744, 1993.
[27] E. Na¨slund, J. Bogefors, S. Skogar et al., “GLP-1 slows solid
gastric emptying and inhibits insulin, glucagon, and PYY
release in humans,” American Journal of Physiology: Regu-
latory, Integrative and Comparative Physiology, vol. 277, no. 3,
pp. R910–R916, 1999.
[28] S. Andreasen, Ghrelin Elisa Kit, 2015.
[29] Special Assays: Monitoring of Amino Acid on Request, 2016,
http://www.zfs-reutlingen.de.
[30] O. K. Zaki, L. El-Wakeel, Y. Ebeid et al., “(e use of glyco-
macropeptide in dietary management of phenylketonuria,”
Journal of Nutrition and Metabolism, vol. 2016, 5 pages, 2016.
[31] A. Pinto, M. F. Almeida, P. C. Ramos et al., “Nutritional status
in patients with phenylketonuria using glycomacropeptide as
their major protein source,” European Journal of Clinical
Nutrition, vol. 71, no. 10, pp. 1230–1234, 2017.
[32] M. Luciana, J. Sullivan, and C. A. Nelson, “Associations
between phenylalanine-to-tyrosine ratios and performance on
tests of neuropsychological function in adolescents treated
early and continuously for phenylketonuria,” Child Devel-
opment, vol. 72, no. 6, pp. 1637–1652, 2001.
[33] Neelima, R. Sharma, Y. S. Rajput, and B. Mann, “Chemical
and functional properties of glycomacropeptide (GMP) and
its role in the detection of cheese whey adulteration in milk:
a review,” Dairy Science and Technology, vol. 93, no. 1,
pp. 21–43, 2013.
[34] J. Pietz, A. Rupp, F. Ebinger et al., “Cerebral energy meta-
bolism in phenylketonuria: ﬁndings by quantitative in vivo
31P MR spectroscopy,” Pediatric Research, vol. 53, no. 4,
pp. 654–662, 2003.
[35] J. Pietz, R. Kreis, A. Rupp et al., “Large neutral amino acids
block phenylalanine transport into brain tissue in patients
with phenylketonuria,” Journal of Clinical Investigation,
vol. 103, no. 8, pp. 1169–1178, 1999.
[36] V. Leuzzi, M. Tosetti, D. Montanaro et al., “(e pathogenesis
of the white matter abnormalities in phenylketonuria. A
multimodal 3.0 tesla MRI and magnetic resonance spec-
troscopy (1H MRS) study,” Journal of Inherited Metabolic
Disease, vol. 30, no. 2, pp. 209–216, 2007.
[37] F. J. van Spronsen, M. J. de Groot, M. Hoeksma,
D. J. Reijngoud, and M. van Rijn, “Large neutral amino acids
in the treatment of PKU: from theory to practice,” Journal of
Inherited Metabolic Disease, vol. 33, no. 6, pp. 671–676, 2010.
[38] G. M. Knudsen, S. Hasselbalch, P. B. Toft, E. Christensen,
O. B. Paulson, and H. Lou, “Blood-brain barrier transport of
amino acids in healthy controls and in patients with phe-
nylketonuria,” Journal of Inherited Metabolic Disease, vol. 18,
no. 6, pp. 653–664, 1995.
[39] S. Schindeler, S. Ghosh-Jerath, S.(ompson et al., “(e eﬀects
of large neutral amino acid supplements in PKU: an MRS and
neuropsychological study,” Molecular Genetics and Meta-
bolism, vol. 91, no. 1, pp. 48–54, 2007.
[40] S. Yano, K. Moseley, and C. Azen, “Large neutral amino acid
supplementation increases melatonin synthesis in phenyl-
ketonuria: a new biomarker,” Journal of Pediatrics, vol. 162,
no. 5, pp. 999–1003, 2013.
[41] M. Bik-Multanowski and J. J. Pietrzyk, “LAT1 gene var-
iants—potential factors inﬂuencing the clinical course of
phenylketonuria,” Journal of Inherited Metabolic Disease,
vol. 29, no. 5, p. 684, 2006.
[42] R. Koch, “Large neutral amino acid therapy and phenylke-
tonuria: a promising approach to treatment,” Molecular
Genetics and Metabolism, vol. 79, no. 2, pp. 110–113, 2003.
[43] M. K. Jordan, R. L. Brunner, M. M. Hunt, and H. K. Berry,
“Preliminary support for the oral administration of valine,
isoleucine and leucine for phenylketonuria,” Developmental
Medicine and Child Neurology, vol. 27, no. 1, pp. 33–39, 1985.
[44] E. L.MacLeod,M. K. Clayton, S. C. van Calcar, and D.M. Ney,
“Breakfast with glycomacropeptide compared with amino
acids suppresses plasma ghrelin levels in individuals with
phenylketonuria,” Molecular Genetics and Metabolism,
vol. 100, no. 4, pp. 303–308, 2010.
[45] K. H. Schulpis, I. Papassotiriou, M. Vounatsou,
G. A. Karikas, S. Tsakiris, and G. P. Chrousos, “Morning
preprandial plasma ghrelin and catecholamine concentra-
tions in patients with phenylketonuria and normal controls:
evidence for catecholamine-mediated ghrelin regulation,”
Journal of Clinical Endocrinology and Metabolism, vol. 89,
no. 8, pp. 3983–3987, 2004.
[46] D. M. Ney, B. M. Stroup, M. K. Clayton et al., “Glyco-
macropeptide for nutritional management of phenylketon-
uria: a randomized, controlled, crossover trial,” American
Journal of Clinical Nutrition, vol. 104, no. 2, pp. 334–345, 2016.
Journal of Nutrition and Metabolism 11
Stem Cells 
International
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
MEDIATORS
INFLAMMATION
of
Endocrinology
International Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Disease Markers
Hindawi
www.hindawi.com Volume 2018
BioMed 
Research International
Oncology
Journal of
Hindawi
www.hindawi.com Volume 2013
Hindawi
www.hindawi.com Volume 2018
Oxidative Medicine and 
Cellular Longevity
Hindawi
www.hindawi.com Volume 2018
PPAR Research
Hindawi Publishing Corporation 
http://www.hindawi.com Volume 2013www.hindawi.com
The Scientific 
World Journal
8
Immunology Research
Hindawi
www.hindawi.com Volume 2018
Journal of
Obesity
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
 Computational and  
Mathematical Methods 
in Medicine
Hindawi
www.hindawi.com Volume 2018
Behavioural 
Neurology
Ophthalmology
Journal of
Hindawi
www.hindawi.com Volume 2018
Diabetes Research
Journal of
Hindawi
www.hindawi.com Volume 2018
Hindawi
www.hindawi.com Volume 2018
Research and Treatment
AIDS
Hindawi
www.hindawi.com Volume 2018
Gastroenterology 
Research and Practice
Hindawi
www.hindawi.com Volume 2018
Parkinson’s 
Disease
Evidence-Based 
Complementary and
Alternative Medicine
Volume 2018
Hindawi
www.hindawi.com
Submit your manuscripts at
www.hindawi.com
